Skip to main content

Table 1 FDA approved drugs targeting VEGF/VEGFR pathways

From: Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

Name Company Type Main target(s) Approved for
Bevacizumab (Avastin) Genentech/Roche Humanized monoclonal antibody VEGF-A Metastatic colorectal carcinoma, non-small cell lung carcinoma, advanced glioblastoma, metastatic renal cell carcinoma
Sorafenib (Nexavar) Bayer/Onyx Small molecule TK inhibitor VEGFR, PDGFR, Raf, cKit, FLT3 Advanced renal cell and hepatocellular carcinomas
Axitinib (Inlyta) Pfizer Small molecule TK inhibitor VEGFR, PDGFR, cKit Renal cell carcinoma
Pazopanib (Votrient) GSK Small molecule TK inhibitor VEGFR, PDGFR, cKit Advanced renal cell carcinoma, soft tissue sarcoma
Vandetanib (Caprelsa) AstraZeneca Small molecule TK inhibitor VEGFR, EGFR, RET Medullary thyroid cancer
Zaltrap (VEGF trap) Regeneron/Sanofi-aventis Fusion protein of Fc with VEGFR1 and R2 domains VEGF, PlGF Metastatic colorectal cancer
Ramucirumab (Cyramza) Lilly/Imclone Human monoclonal antibody VEGFR2 Gastric/gastroesophageal junction adenocarcinoma, colorectal carcinoma, non-small cell lung carcinoma
\